VSEE HEALTH, INC. (VSEE): Nasdaq/NYSE listing notice — Digital Health Acquisition Corp. receives Nasdaq delisting notice for MVLS below $50M

VSEE HEALTH, INC.

Received Nasdaq letter on March 31, 2023 for failing to meet $50M Market Value of Listed Securities requirement.
Securities (common stock, units, warrants) traded below threshold for 30 consecutive trading days.
Has 180 days until September 27, 2023 to regain compliance by closing at $50M+ for 10 consecutive business days.
May transfer to Nasdaq Capital Market if unable to regain compliance by the deadline.
Company states no assurance it can regain or maintain compliance with Nasdaq Global listing standards.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

VSEE HEALTH, INC. received a nasdaq deficiency notice notice regarding market value (rules 5450, 5810).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450, 5810

Exact text from the filing

March 31, 2023, Digital Health Acquisition Corp., a Delaware corporation (the “Company”), received a letter (the “Letter”) from the staff at The Nasdaq Global Market (“Nasdaq Global”) notifying the Company that for the 30 consecutive trading days prior to the date of the Letter, the Company’s securities listed on Nasdaq Global (including the Common Stock, Units and Warrants) (the “Securities”) had traded at a value below the minimum $50,000,000 “Market Value of Listed Securities” (“MVLS”) requirement set forth in Nasdaq Listing Rule 5450(b)(2)(A), which is required for continued listing of the

View on SEC.gov

Browse all listing & compliance notices →

VSEE HEALTH, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-042783

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.